These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15454208)

  • 1. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
    Batt DG; Qiao JX; Modi DP; Houghton GC; Pierson DA; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5269-73. PubMed ID: 15454209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.
    Qiao JX; Cheng X; Modi DP; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
    Bioorg Med Chem Lett; 2005 Jan; 15(1):29-35. PubMed ID: 15582405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
    Wang S; Beck R; Burd A; Blench T; Marlin F; Ayele T; Buxton S; Dagostin C; Malic M; Joshi R; Barry J; Sajad M; Cheung C; Shaikh S; Chahwala S; Chander C; Baumgartner C; Holthoff HP; Murray E; Blackney M; Giddings A
    J Med Chem; 2010 Feb; 53(4):1473-82. PubMed ID: 20121197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel hydroxy pyrazole based factor IXa inhibitor.
    Vijaykumar D; Sprengeler PA; Shaghafi M; Spencer JR; Katz BA; Yu C; Rai R; Young WB; Schultz B; Janc J
    Bioorg Med Chem Lett; 2006 May; 16(10):2796-9. PubMed ID: 16487703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
    Qiao JX; Cheng X; Smallheer JM; Galemmo RA; Drummond S; Pinto DJ; Cheney DL; He K; Wong PC; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1432-7. PubMed ID: 17174550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
    Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR
    J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
    Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
    Katakura S; Nagahara T; Hara T; Iwamoto M
    Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.
    Matter H; Will DW; Nazaré M; Schreuder H; Laux V; Wehner V
    J Med Chem; 2005 May; 48(9):3290-312. PubMed ID: 15857135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
    Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
    Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.
    Wang S; Beck R; Blench T; Burd A; Buxton S; Malic M; Ayele T; Shaikh S; Chahwala S; Chander C; Holland R; Merette S; Zhao L; Blackney M; Watts A
    J Med Chem; 2010 Feb; 53(4):1465-72. PubMed ID: 20121198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
    Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
    Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
    Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
    Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.